Immune modulatory effects of oncogenic KRAS in cancer

Nature·Oct 28

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Research is exploring the role of oncogenic KRAS in cancer, including its effects on immune modulation. Studies suggest that KRAS mutations may contribute to immune suppression and cancer progression in various types of cancer, such as colorectal, lung, and pancreatic cancer. The understanding of KRAS's immune modulatory effects is being investigated as a potential target for cancer therapy.

Full coverage

Oncogenic KRAS mutations drive immune suppression through immune-related regulatory network and metabolic reprogramming

Nature·Nov 3

Common oncogenic mutations in colorectal cancer: drivers of carcinogenesis and potential therapeutic targets

Frontiers·Apr 7

Allele-specific KRAS signaling: shaping tumor immunity and therapeutic response in lung adenocarcinoma

Nature·May 28

Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges

Nature·Nov 28

Loss of MicroRNA-29b promotes DNMT3b-mediated STING downregulation to attenuate radiotherapy-induced antitumor immunity in KRAS-mutated colorectal cancer

Nature·Jan 28

KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression

Frontiers·Apr 20

Small molecular inhibitors for KRAS-mutant cancers

Frontiers·Aug 17

MYC at the tumor–immune interface: mechanisms of immune escape and immunotherapy resistance

Frontiers·Jan 5

View original report at Nature ↗

Fetching the latest headlines…